DIA
SRPT icon

Dana Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Dana Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,974
Closed -$477K – 295
2020
Q2 		$477K Buy
+2,974
New +$405K 0.03% 225
2020
Q1 		– Sell
-2,514
Closed -$324K – 314
2019
Q4 		$324K Sell
2,514
-632
-20% -$63.8K 0.02% 254
2019
Q3 		$237K Buy
3,146
+898
+40% +$106K 0.01% 249
2019
Q2 		$342K Sell
2,248
-20,139
-90% -$2.45M 0.02% 239
2019
Q1 		$2.67M Buy
+22,387
New +$2.88M 0.13% 112

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dana Investment Advisors's SRPT Position: Q3 2020 in Review

Dana Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2020, closing a stake of 2,974 shares — an estimated $477K sold.

Dana Investment Advisors first reported a position in SRPT in Q1 2019 and held it in 5 quarters. The position peaked at $2.67M in Q1 2019. 403 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

  • Dana Investment Advisors reported no remaining Sarepta Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Dana Investment Advisors sold 2,974 Sarepta Therapeutics shares in Q3 2020, an estimated $477K.
  • Dana Investment Advisors first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 5 quarters.
  • Dana Investment Advisors's Sarepta Therapeutics position peaked at $2.67M in Q1 2019.
  • 403 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on Dana Investment Advisors's 13F filing for Q3 2020, filed 10 Nov 2020.